Hepatitis C: INNX started an open-label extension of a Phase II study in 34 of the 35 patients enrolled in the original study. The protocol calls for 6 E1 vacci

Innogenetics N.V. (EASD:INNX), Ghent, Belgium Product: Hepatitis C (HCV) E1 vaccine Business: Infectious diseases Therapeutic category: Viral infection Target: Immune cells Description: Efficacy as a...